Soliris prevents an aHUS relapse after a kidney transplant, meta-analysis finds
Relapses were less likely in people with atypical hemolytic uremic syndrome (aHUS) treated with Soliris (eculizumab) after a kidney transplant, and they had better kidney function and a lower risk of transplant rejection, according to a meta-analysis of published studies. “This meta-analysis … demonstrated that [Soliris] produced meaningful…